All In Biotech

Drug Trial Radar · NCT02435095

Antipsychotic Induced Structural and Functional Brain Changes

Are Antipsychotics Neurotoxic or Neuroprotective? A Long-term Comparison of Two Treatment Strategies

Last checked: Nov 20, 2026Latest source record: Nov 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 174 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

174

Actual

Start

May 2015

Primary completion

Aug 2020

Study completion Aug 2020

Sponsor

Lead sponsor
RWTH Aachen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 6, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Continuation of antipsychotic drug treatment for at least 12 months after remission of the first psychotic episode represents the gold clinical standard, and it is recommended by all international treatment guidelines. Numerous studies have shown that the risk of relapse is significantly increased, if drug treatment is terminated prematurely. However, only a minority of patients achieve functional remission, even if they fully comply with treatment. Long-term adverse effects of the currently available drugs, specifically brain grey matter loss and development of supersensitivity psychosis, might outweigh their benefits. Thus, the current standard of long-term maintenance antipsychotic treatment, which has the primary goal of relapse prevention, has to be questioned. Here the investigators hypothesize that intermittent treatment (experimental) with antipsychotics, which is directed exclusively against the positive symptoms of Schizophrenia, is associated with less loss in total grey matter volume than maintenance treatment (control). Furthermore, the investigators hypothesise that this targeted treatment approach is associated with better functional outcome (fewer negative symptoms, better cognitive performance, better quality of life) than continuous antipsychotic treatment,although the latter is initially associated with fewer relapses.The aim of the present study is to compare two different drug therapies -maintenance therapy versus on-demand, intermittent therapy- in terms of their treatment's success and the structural changes in the brain.

Conditions

  • Schizophrenia

Interventions

  • Maintenance treatmentDrug

    Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months. All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).

  • Intermittent treatmentDrug

    Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms. All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total grey matter volumeTime frame: over 12 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Alexianer Aachen GmbH

    Aachen, Germany

  • Zentrum für Neurologie und Seelische Gesundheit im Kapuziner Karree Aachen

    Aachen, Germany

  • LVR Klinik Bonn

    Bonn, Germany

  • LVR Klinik Düren

    Düren, Germany

  • Klinik und Poliklinik für Psychiatrie und Psychotherapie der Heinrich-Heine-Universität Düsseldorf

    Düsseldorf, Germany

  • LVR Klinik Essen

    Essen, Germany

  • ViaNobis Gangelt

    Gangelt, Germany

  • Klinik Königshof (Abteilung für Allgemeine Psychiatrie)

    Krefeld, Germany

  • LVR Klinik Langenfeld

    Langenfeld, Germany

  • LVR Klinik Viersen

    Viersen, Germany

  • RWTH University Hospital Aachen

    Aachen, North Rhine-Westphalia, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.